Despite the immense success of osimertinib in first- and second-line treatment, patients with EGFR-mutant NSCLC typically experience disease progression within two years of initiating therapy due to evolving resistance mechanisms that can be broadly categorized into acquired and intrinsic types [30]. Here, EGFR is linked to non-small cell lung carcinoma.